Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development and commercialization of therapies for the treatment of rare diseases. The company is headquartered in San Diego, California.
| Revenue (TTM) | $536.20M |
| Gross Profit (TTM) | $299.98M |
| EBITDA | $16.09M |
| Operating Margin | -29.00% |
| Return on Equity | -69.40% |
| Return on Assets | -6.46% |
| Revenue/Share (TTM) | $5.95 |
| Book Value | $1.07 |
| Price-to-Book | 41.85 |
| Price-to-Sales (TTM) | 7.71 |
| EV/Revenue | 7.82 |
| EV/EBITDA | 108.85 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 55.60% |
| Shares Outstanding | $92.99M |
| Float | $87.02M |
| % Insiders | 0.78% |
| % Institutions | 113.97% |
Volatility is currently contracting